BRIEF published on 06/06/2024 at 13:05, 2 years 3 months ago Theralase détruit avec succès le cancer du poumon Technologies Théralase Cancer Du Poumon Rutherrin® Étude Préclinique
PRESS RELEASE published on 06/06/2024 at 13:00, 2 years 3 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 2 years 3 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
BRIEF published on 06/04/2024 at 13:05, 2 years 3 months ago Technologie Theralase® efficace pour l'inactivation des virus Theralase Ruvidar Recherche Antivirale Heliyon Inactivation Des Virus
PRESS RELEASE published on 06/04/2024 at 13:00, 2 years 3 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
BRIEF published on 05/30/2024 at 13:05, 2 years 4 months ago Theralase Releases 1Q2024 Financial Statements Financial Results Cancer Treatment Theralase Study II PDCs
BRIEF published on 05/30/2024 at 13:05, 2 years 4 months ago Theralase publie ses états financiers du 1T2024 Résultats Financiers Traitement Du Cancer Theralase Étude II PDC
PRESS RELEASE published on 05/30/2024 at 13:00, 2 years 4 months ago Theralase(R) Release's 1Q2024 Financial Statements Theralase® releases unaudited interim consolidated 1Q2024 financial statements. Company to host conference call on June 6th, 2024. Study II update and Break Through Designation progress discussed Conference Call Financial Statements Break Through Designation Theralase Study II
BRIEF published on 04/24/2024 at 13:05, 2 years 5 months ago Theralase Technologies Inc. Completes $750,200 Funding Round Private Placement Pharmaceuticals Clinical Research Investment Theralase Technologies
BRIEF published on 04/24/2024 at 13:05, 2 years 5 months ago Theralase Technologies Inc. finalise une ronde de financement de 750 200 $ Investissement Placement Privé Médicaments Recherche Clinique Technologies Théralase
Published on 10/01/2026 at 08:02, 2 hours 22 minutes ago Southern Energy Announces Results of Annual Meeting and Board Changes
Published on 10/01/2026 at 01:21, 9 hours 3 minutes ago Revival Gold Announces Filing of Final Base Shelf Prospectus
Published on 10/01/2026 at 01:00, 9 hours 24 minutes ago Algo Grande Copper Secures Five-Year Surface Access Agreement With Ejido Palos Chinos at the Adelita Project
Published on 09/30/2026 at 23:30, 10 hours 54 minutes ago Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.
Published on 09/30/2026 at 20:35, 13 hours 49 minutes ago Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited
Published on 10/01/2026 at 10:15, 9 minutes ago OLB Completes Previously Announced Management Board Appointments
Published on 10/01/2026 at 10:12, 11 minutes ago DN Group AG strengthens senior management with sustainability expert Antje Biber
Published on 10/01/2026 at 10:05, 19 minutes ago Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables
Published on 10/01/2026 at 10:00, 24 minutes ago iOmx Therapeutics Appoints Rüdiger Wolff as Chief Financial Officer
Published on 10/01/2026 at 09:54, 30 minutes ago Septembre 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 10/01/2026 at 08:30, 1 hour 54 minutes ago Eurazeo opens an office in Abu Dhabi, reinforcing its commitment to the Middle East
Published on 10/01/2026 at 08:30, 1 hour 54 minutes ago Cegedim Business Services dévoile Hospi-DM, sa nouvelle offre SaaS de traçabilité des dispositifs médicaux, lors des 36èmes Journées Euro-Pharmat
Published on 10/01/2026 at 08:30, 1 hour 54 minutes ago Eurazeo ouvre un bureau à Abu Dhabi et renforce son engagement au Moyen-Orient
Published on 10/01/2026 at 08:00, 2 hours 24 minutes ago CNP Assurances and Embracon complete their combination to create a leading consórcio player in Brazil
